A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling

References

• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21 - 34; PMID: 10840932
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225 - 49; http://dx.doi.org/10.3322/caac.20006; PMID: 19474385
   PubMed Web of Science ®Google Scholar
• Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomark 2010; 9:267 - 86; PMID: 22112480
   PubMed Web of Science ®Google Scholar
• Garber K. Cancer research. Melanoma drug vindicates targeted approach. Science (New York, NY 2009; 326:1619.
   Google Scholar
• Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005; 1059:16 - 25; http://dx.doi.org/10.1196/annals.1339.005; PMID: 16382039
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 2011; 71:7137 - 40; http://dx.doi.org/10.1158/0008-5472.CAN-11-1243; PMID: 22131348
   PubMed Web of Science ®Google Scholar
• Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011; 6:e28973; http://dx.doi.org/10.1371/journal.pone.0028973; PMID: 22194965
   PubMed Web of Science ®Google Scholar
• Deng W, Vashisht Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2011.
   Google Scholar
• Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, et al. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 2011; 13:1132 - 42; PMID: 22241959
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4:97 - 105; http://dx.doi.org/10.1038/nrc1275; PMID: 14964307
   PubMed Web of Science ®Google Scholar
• Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010; 10:342 - 52; http://dx.doi.org/10.1038/nrc2842; PMID: 20414202
   PubMed Web of Science ®Google Scholar
• Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16:34 - 44; http://dx.doi.org/10.2174/138161210789941865; PMID: 20214616
   PubMed Web of Science ®Google Scholar
• Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004; 117:989 - 98; http://dx.doi.org/10.1242/jcs.01111; PMID: 14996930
   PubMed Web of Science ®Google Scholar
• Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21:7001 - 10; http://dx.doi.org/10.1038/sj.onc.1205859; PMID: 12370822
   PubMed Web of Science ®Google Scholar
• Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000; 19:5419 - 27; http://dx.doi.org/10.1038/sj.onc.1203947; PMID: 11114718
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415 - 21; http://dx.doi.org/10.1126/science.8197455; PMID: 8197455
   PubMed Web of Science ®Google Scholar
• Wojcik EJ, Sharifpoor S, Miller NA, Wright TG, Watering R, Tremblay EA, et al. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006; 25:2773 - 84; http://dx.doi.org/10.1038/sj.onc.1209306; PMID: 16407846
   PubMed Web of Science ®Google Scholar
• Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol Cancer 2007; 6:69; http://dx.doi.org/10.1186/1476-4598-6-69; PMID: 17967179
   PubMed Web of Science ®Google Scholar
• Hbibi AT, Lagorce C, Wind P, Spano JP, Des Guetz G, Milano G, et al. Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value. Cancer Biomark 2008; 4:83 - 91; PMID: 18503159
   PubMed Web of Science ®Google Scholar
• Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006; 2006:pe30; http://dx.doi.org/10.1126/stke.3432006pe30; PMID: 16835434
   PubMedGoogle Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228:273 - 87; http://dx.doi.org/10.1111/j.1600-065X.2008.00754.x; PMID: 19290934
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005; 24:315 - 27; http://dx.doi.org/10.1007/s10555-005-1580-1; PMID: 15986140
   PubMed Web of Science ®Google Scholar
• Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88:435 - 7; http://dx.doi.org/10.1016/S0092-8674(00)81883-8; PMID: 9038334
   PubMed Web of Science ®Google Scholar
• Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376:599 - 602; http://dx.doi.org/10.1038/376599a0; PMID: 7637810
   PubMed Web of Science ®Google Scholar
• Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81:727 - 36; http://dx.doi.org/10.1016/0092-8674(95)90534-0; PMID: 7774014
   PubMed Web of Science ®Google Scholar
• Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002; 43:1763 - 8; http://dx.doi.org/10.1080/1042819021000006295; PMID: 12685829
   PubMed Web of Science ®Google Scholar
• Cheng LH. The study on the extraction method of indirubin from Indigo Naturalis. Zhong Yao Cai 2007; 30:50 - 2; PMID: 17539304
   PubMedGoogle Scholar
• Meijer L. [Mediterranean purple indirubins: a source of GSK-3 inhibitors]. Med Sci (Paris) 2004; 20:516 - 8; http://dx.doi.org/10.1051/medsci/2004205516; PMID: 15190467
   PubMed Web of Science ®Google Scholar
• Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, et al. 6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 2011; 71:3972 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-10-3852; PMID: 21610112
   PubMed Web of Science ®Google Scholar
• Ferandin Y, Bettayeb K, Kritsanida M, Lozach O, Polychronopoulos P, Magiatis P, et al. 3′-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. J Med Chem 2006; 49:4638 - 49; http://dx.doi.org/10.1021/jm060314i; PMID: 16854069
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, et al. 5,5′-substituted indirubin-3′-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem 2010; 53:3696 - 706; http://dx.doi.org/10.1021/jm100080z; PMID: 20361800
   PubMed Web of Science ®Google Scholar
• Ribas J, Bettayeb K, Ferandin Y, Knockaert M, Garrofé-Ochoa X, Totzke F, et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death. Oncogene 2006; 25:6304 - 18; http://dx.doi.org/10.1038/sj.onc.1209648; PMID: 16702956
   PubMed Web of Science ®Google Scholar
• Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275:10761 - 6; http://dx.doi.org/10.1074/jbc.275.15.10761; PMID: 10753867
   PubMed Web of Science ®Google Scholar
• Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 2008; 105:10853 - 8; http://dx.doi.org/10.1073/pnas.0804821105; PMID: 18664580
   PubMed Web of Science ®Google Scholar
• Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 2004; 47:935 - 46; http://dx.doi.org/10.1021/jm031016d; PMID: 14761195
   PubMed Web of Science ®Google Scholar
• Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513 - 609; http://dx.doi.org/10.1146/annurev.cellbio.13.1.513; PMID: 9442882
   PubMed Web of Science ®Google Scholar
• Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, et al. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 2000; 275:24935 - 44; http://dx.doi.org/10.1074/jbc.M002383200; PMID: 10823829
   PubMed Web of Science ®Google Scholar
• Lee JT, Herlyn M. MEK’ing the most of p53 reactivation therapy in melanoma. J Invest Dermatol 2012; 132:263 - 5; http://dx.doi.org/10.1038/jid.2011.362; PMID: 22241441
   PubMed Web of Science ®Google Scholar
• Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 2010; 80:624 - 37; http://dx.doi.org/10.1016/j.bcp.2010.04.029; PMID: 20450891
   PubMed Web of Science ®Google Scholar